{"product_id":"rfl-pestle-analysis","title":"(RFL) Rafael Holdings, Inc. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Rafael Holdings, Inc. PESTLE Analysis explains the political, economic, social, technological, legal, and environmental forces shaping the company and why that matters for strategy and investment. The page includes a real preview\/sample of the report so you can assess style and depth; purchase the full version to receive the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS FDA oversight for 2 Phase III trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRafael Holdings’ CPI-613 (devimistat) sits at a critical FDA gate: the company has 2 pivotal Phase III registrational trials, so U.S. oversight can make or break the path to approval.\u003c\/p\u003e\n\u003cp\u003eAny shift in FDA oncology review standards or timing can delay readouts, add protocol changes, and raise development spend across both studies.\u003c\/p\u003e\n\u003cp\u003eThat matters because Phase III trials are the most capital-heavy stage, and even small FDA requests can push timelines by months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS and Israel cross-border exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRafael Holdings’ U.S. and Israel assets expose it to two policy regimes, so changes in taxes, permits, sanctions, or capital rules can hit operations fast. U.S.-Israel trade topped $50 billion in 2024, so any bilateral friction can affect cross-border flow and investor confidence. Political stability matters in both markets, because security shocks in Israel or policy shifts in the U.S. can disrupt continuity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew Jersey headquarters and local policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRafael Holdings is based in Newark, New Jersey, so state and city policy can move costs fast. New Jersey’s corporate business tax reaches 11.5% on income above $1 million, and permits, zoning, and local incentives can affect both headquarters and real estate assets. Newark’s infrastructure spending and economic-development programs also matter for tenant demand and project timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHealthcare reimbursement policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRafael Holdings, Inc.’s drug pipeline still depends on payer and government reimbursement, and oncology prices face heavy pushback from public and private insurers. Medicare covers about 66 million Americans, so policy shifts can quickly change access, uptake, and revenue. \u003c\/p\u003e\n\u003cp\u003eFor commercial launch, even strong clinical data is not enough if coding, formulary placement, or prior authorization slows use. The Inflation Reduction Act’s Medicare negotiation path adds more pricing pressure, so future oncology margins may move with reimbursement rules as much as with science.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReimbursement drives market access.\u003c\/li\u003e\n\u003cli\u003eOncology pricing faces insurer pressure.\u003c\/li\u003e\n\u003cli\u003ePolicy shifts can cut revenue fast.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommercial real estate zoning and public-use rules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRafael Holdings, Inc.’s real estate segment includes a commercial office complex with an 800-space public parking facility, so city and county zoning rules directly affect how much space can be leased and how the site can be used.\u003c\/p\u003e\n\u003cp\u003ePublic-access, building, and parking rules can raise compliance costs fast, especially when local officials tighten use permits or change occupancy limits. One city decision can alter tenant mix, foot traffic, and rental demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e800 public parking spaces shape tenant access\u003c\/li\u003e\n\u003cli\u003eLocal zoning controls allowable uses\u003c\/li\u003e\n\u003cli\u003ePublic-use rules affect leasing flexibility\u003c\/li\u003e\n\u003cli\u003eCity and county policy can lift costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor Rafael Holdings, Inc., political risk is less about federal policy and more about local approvals, inspections, and rule changes that can delay leasing or require added spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA and Policy Risks Weigh on Rafael Holdings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRafael Holdings faces high political risk from FDA oncology oversight, because its CPI-613 program still needs U.S. review to reach approval. Cross-border exposure also matters: U.S.-Israel goods trade topped $50 billion in 2024, so policy friction can hit operations and sentiment. New Jersey tax and zoning rules can also lift costs and delay leasing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePolitical factor\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA oversight\u003c\/td\u003e\n\u003ctd\u003e2 Phase III trials\u003c\/td\u003e\n\u003ctd\u003eApproval timing risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S.-Israel trade\u003c\/td\u003e\n\u003ctd\u003e$50B+ in 2024\u003c\/td\u003e\n\u003ctd\u003eCross-border exposure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Jersey tax\u003c\/td\u003e\n\u003ctd\u003e11.5%\u003c\/td\u003e\n\u003ctd\u003eHigher operating cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes how Political, Economic, Social, Technological, Environmental, and Legal forces shape Rafael Holdings, Inc.’s risks, opportunities, and strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise Rafael Holdings, Inc. PESTLE snapshot for fast risk review and easy sharing in planning meetings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable sources list linking each key claim to industry reports, datasets, and benchmarks to speed due diligence and boost model credibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial office leasing revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRafael Holdings, Inc.’s office leasing income depends on occupancy and lease rates, so weak demand can cut rent and lift vacancy risk. U.S. office vacancy stayed near 19% in 2025, still pressuring owners with rent resets and longer leasing cycles. Stronger leasing terms lift recurring cash flow and make the real estate unit more stable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital-intensive clinical development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePharmaceutical development is brutally capital-heavy: a single Phase III trial can run for years and enroll hundreds to thousands of patients, while R and D spends often tops 15% to 20% of revenue in drug developers. Rafael Holdings, Inc. faces that same squeeze because two Phase III registrational studies must be funded before any product sales begin. That makes access to equity, debt, or strategic capital critical, especially when cash burn rises faster than revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech valuation and financing cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiotech valuations stay tied to risk appetite: when rates remain high, early-stage drug assets usually face lower multiples and tougher fundraises. In 2025, the Federal Reserve kept rates in the 4.25% to 4.50% range, which still pressured higher-risk capital and made clinical-stage financing more selective. For Rafael Holdings, Inc., that can slow asset re-pricing and raise dilution risk if follow-on funding comes at weaker terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInterest-rate pressure on real estate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHigher rates kept refinancing costs elevated, with the U.S. 10-year Treasury near 4% in 2025, and that feeds straight into commercial real estate cap rates and valuations. For Rafael Holdings, Inc., that can squeeze asset income and lower net asset value when debt resets or property values are marked down.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher debt service cuts cash flow.\u003c\/li\u003e\n\u003cli\u003eCap rates rise, values fall.\u003c\/li\u003e\n\u003cli\u003eNet asset value can drop fast.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat makes leverage and lease renewals more sensitive to every rate move.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUSD and ILS currency exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRafael Holdings, Inc. faces USD and ILS exposure because it holds operations and investments in the United States and Israel. A move in USD\/ILS can lift or reduce the U.S. dollar value of Israeli assets and liabilities, even when local performance is stable. In 2025, this matters more because Israel-linked costs and receipts are often settled in shekels, while reporting is in dollars.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUSD\/ILS moves change reported asset values.\u003c\/li\u003e\n\u003cli\u003eShekel costs can rise in dollar terms.\u003c\/li\u003e\n\u003cli\u003eHedging can reduce, not remove, volatility.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigher Rates and Office Weakness Pressure Rafael Holdings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigher rates still matter most for Rafael Holdings, Inc.: the Fed held 4.25% to 4.50% in 2025 and the U.S. 10-year stayed near 4%, keeping debt and cap rates high. Office vacancy near 19% in 2025 also kept leasing pressure on rent and renewals. Biotech funding stayed selective, so Phase III spending raises dilution risk. USD\/ILS swings can also move reported value.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003cth\u003eEffect\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds\u003c\/td\u003e\n\u003ctd\u003e4.25%-4.50%\u003c\/td\u003e\n\u003ctd\u003eHigher funding cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10-year U.S. Treasury\u003c\/td\u003e\n\u003ctd\u003eNear 4%\u003c\/td\u003e\n\u003ctd\u003eHigher cap rates\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOffice vacancy\u003c\/td\u003e\n\u003ctd\u003eNear 19%\u003c\/td\u003e\n\u003ctd\u003eWeak rent growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eRafael Holdings, Inc. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Rafael Holdings, Inc. PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use, with no placeholders or surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced pancreatic cancer unmet need\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn the U.S., pancreatic cancer has about a 13% 5-year relative survival rate, so patients and oncologists keep looking for better options. CPI-613’s trial in advanced pancreatic cancer can benefit from this unmet need, which can support enrollment and, if data are strong, future adoption. High mortality also keeps caregiver and advocacy attention high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRelapsed refractory AML burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRafael Holdings, Inc.'s lead candidate targets relapsed or refractory AML, where many patients have few options and survival stays poor. AML causes about 20,800 new U.S. cases and 11,200 deaths a year, and relapsed\/refractory cases often need new therapies fast. That keeps social demand for better oncology drugs high, even as treatment gaps remain wide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAging population in major markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCancer incidence rises with age, so aging in major markets supports Rafael Holdings, Inc.’s oncology demand. The United States had about 59 million people aged 65 and older in 2024, and Israel had roughly 1.2 million, widening the patient pool for cancer care. This trend can also support the pharmaceutical pipeline as older populations need more long-term treatment options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHospital and trial enrollment behavior\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical success hinges on patients agreeing to join trials, and physician referrals plus hospital site support can speed or stall enrollment. When enrollment slows, readouts slip and trial burn rises, which matters for Rafael Holdings, Inc.'s cash use and timelines. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatient consent drives trial pace.\u003c\/li\u003e\n\u003cli\u003ePhysician referrals shape site flow.\u003c\/li\u003e\n\u003cli\u003eSlow enrollment delays data and raises costs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePost-pandemic office usage patterns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePost-pandemic office use still reflects hybrid work, with U.S. office vacancy near 19.9% in Q2 2024, which keeps leasing demand uneven for Rafael Holdings, Inc. Social preferences now favor flexible space, strong amenities, and transit-friendly locations, not just square footage.\u003c\/p\u003e\n\u003cp\u003eThat shift matters because tenants are more selective, so older or less central buildings face weaker pricing power. Kastle Systems’ office swipes have also stayed around half of pre-pandemic levels in many big-city markets, showing that attendance remains below 2019 norms.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHybrid work trims daily office demand\u003c\/li\u003e\n\u003cli\u003eFlexibility now ranks above size\u003c\/li\u003e\n\u003cli\u003eQuality and location drive renewals\u003c\/li\u003e\n\u003cli\u003eLeasing risk rises for weak assets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWhy Aging Demand Supports Rafael as Office Weakness Persists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAn aging, high-cancer-burden patient base supports Rafael Holdings, Inc., but trial uptake still depends on physician referrals, caregiver support, and patient trust. U.S. office demand stays selective too: vacancy was 19.9% in Q2 2024, so social preference for flexible, amenity-rich space still hurts weaker assets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. 65+\u003c\/td\u003e\n\u003ctd\u003e59M, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIsrael 65+\u003c\/td\u003e\n\u003ctd\u003e1.2M, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. office vacancy\u003c\/td\u003e\n\u003ctd\u003e19.9%, Q2 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCPI-613 devimistat metabolic oncology platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCPI-613, now called devimistat, is Rafael Holdings, Inc.'s lead metabolic oncology asset and aims at energy pathways that differ between healthy and malignant cells. That makes it a niche cancer platform, but its value still depends on clear clinical proof and durable efficacy. In biotech terms, the science is the asset; the trial data sets the price.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2 pivotal Phase III registrational studies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRafael Holdings, Inc. has 2 Phase III registrational studies, so trial tech is a make-or-break factor. Late-stage work depends on eClinical tools like electronic data capture, central monitoring, and real-time analytics to keep data clean and on time.\u003c\/p\u003e\n\u003cp\u003eIn Phase III, even small system errors can delay readouts or weaken trial integrity, and that can push back regulatory filing plans. Strong data systems help protect the timeline and the value of both programs.\u003c\/p\u003e\n\u003cp\u003eWith 2 late-stage trials running, Rafael Holdings, Inc. needs reliable tech control across sites, vendors, and patient data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial data and biomarker analytics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eModern oncology trials need clean data, because FDA review for drug approvals depends on auditable endpoints and biomarker readouts. Biomarker-led trials can narrow patient groups and raise response rates; for example, tumor-agnostic drugs like Keytruda and Vitrakvi rely on genomic signals. Better analytics can cut delays, strengthen submissions, and support Rafael Holdings, Inc.'s oncology pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDrug development manufacturing controls\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRafael Holdings, Inc. depends on scalable manufacturing to move a clinical candidate into a market product, and that step drives both cost and approval speed. FDA drug GMP inspections rose to 625 in FY2025, showing how tight process control, stability testing, and quality systems can decide readiness. Strong controls also reduce batch failures and help keep COGS in check.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScalable plants cut transfer risk.\u003c\/li\u003e\n\u003cli\u003eStability data supports shelf life.\u003c\/li\u003e\n\u003cli\u003eQuality systems speed FDA review.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBuilding systems and parking operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRafael Holdings, Inc. benefits from an integrated 800-space public parking facility, so building systems and parking tech matter for both tenant flow and asset use. Smart automation, security, and parking management can cut operating friction and improve the tenant experience. With tighter control of access, lighting, and space turnover, the property can lift utilization and trim costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e800-space public parking asset\u003c\/li\u003e\n\u003cli\u003eAutomation lowers operating waste\u003c\/li\u003e\n\u003cli\u003eSecurity tech supports tenant comfort\u003c\/li\u003e\n\u003cli\u003eParking systems improve space use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRafael's Edge: Trials, GMP Discipline, and Parking Tech\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRafael Holdings, Inc.'s tech edge rests on devimistat and two Phase III trials, where eClinical tools, clean data capture, and central monitoring can make or break readouts.\u003c\/p\u003e\n\u003cp\u003eIn FY2025, FDA drug GMP inspections reached 625, underscoring how quality systems, stability data, and process control shape approval speed and COGS.\u003c\/p\u003e\n\u003cp\u003eIts 800-space parking asset also needs smart access, security, and space-use tech to lift utilization and trim operating friction.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase III trials\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA GMP inspections FY2025\u003c\/td\u003e\n\u003ctd\u003e625\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eParking spaces\u003c\/td\u003e\n\u003ctd\u003e800\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA investigational drug compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCPI-613 remains in clinical development, so Rafael Holdings, Inc. must stay aligned with FDA investigational drug rules under 21 CFR Part 312, including IND filings, safety reports, and protocol updates. Any missed adverse-event reporting or trial deviation can trigger a clinical hold and slow enrollment. With one asset still dependent on trial execution, even a small compliance lapse can disrupt timelines and value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase III registrational evidence standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRafael Holdings, Inc. faces a high bar in Phase III because the FDA can lean on two pivotal trials, and each one must be adequate and well controlled. Registrational studies are built to support approval decisions, so clean endpoints, prespecified stats, and low bias matter legally. In practice, a primary endpoint usually needs strong significance, often p\u0026lt;0.05, or the case gets weaker fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSEC reporting as a public company\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRafael Holdings, Inc. is a public issuer, so it must file SEC reports like Form 10-K and 10-Q, plus timely 8-K updates under U.S. securities laws. That means financial reporting, risk disclosure, and governance controls are ongoing legal duties, not one-time tasks. Any weakness in disclosure controls can raise enforcement, restatement, and shareholder liability risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatent and exclusivity protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRafael Holdings, Inc. needs strong patent and exclusivity protection because its pharmaceutical value rests on intellectual property. In the US, a patent can run 20 years from filing, while FDA exclusivity can add 5 years for a new chemical entity, 7 years for orphan drugs, or 12 years for biologics. If those rights lapse, competitors can enter fast and cut commercialization value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatent loss cuts pricing power.\u003c\/li\u003e\n\u003cli\u003eExclusivity delays generic entry.\u003c\/li\u003e\n\u003cli\u003eIP strength drives pharma valuation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommercial lease and property law\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRafael Holdings, Inc.'s real estate income depends on lease terms, landlord-tenant law, and property safety compliance; lease enforcement and code breaches can cut rent flow and raise repair costs. The public parking facility adds slip, trip, access, and insurance exposure, so access control and maintenance records matter. In 2025, the U.S. Census Bureau showed national office vacancy near 20%, which keeps lease legal discipline important.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLease terms drive cash flow stability\u003c\/li\u003e\n\u003cli\u003eSafety rules limit liability claims\u003c\/li\u003e\n\u003cli\u003eParking access raises duty-of-care risk\u003c\/li\u003e\n\u003cli\u003eCompliance protects asset income\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRafael Holdings: FDA, SEC, and Patent Risks Can Move Value Fast\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRafael Holdings, Inc. faces tight FDA, SEC, and patent rules, so legal risk is tied to trial conduct, disclosure quality, and IP life. A missed adverse-event filing under 21 CFR Part 312 can trigger a clinical hold, while public-company reporting errors can raise enforcement risk. Patent loss can cut value fast; U.S. patents last 20 years from filing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal factor\u003c\/th\u003e\n\u003cth\u003eKey risk data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA trials\u003c\/td\u003e\n\u003ctd\u003eIND reporting, safety updates\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSEC reporting\u003c\/td\u003e\n\u003ctd\u003e10-K, 10-Q, 8-K duties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent life\u003c\/td\u003e\n\u003ctd\u003e20 years from filing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOffice building energy consumption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOffice buildings are energy-hungry assets: U.S. buildings drive about 40% of energy-related carbon emissions, and HVAC plus lighting are the main loads. For Rafael Holdings, Inc., higher utility rates and tighter emission rules can lift operating expenses, while better insulation, controls, and efficient HVAC can protect margins. Cutting energy use by 10% can quickly improve net operating income.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHVAC and indoor air quality standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTenant health and comfort at Rafael Holdings, Inc. depend on strong ventilation, filtration, and humidity control, and the EPA says indoor air can be 2 to 5 times more polluted than outdoor air. Indoor air quality now weighs more in office leasing, with better HVAC helping meet standards such as ASHRAE 62.1 and supporting healthier spaces. Better systems can lift occupancy and retention, especially as tenants keep favoring buildings with cleaner air and lower sick-building risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e800-space parking footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRafael Holdings, Inc.’s 800-space public parking footprint raises site intensity and can add idle-time emissions, especially if demand stays high. Transportation still makes up about 28% of U.S. greenhouse gas emissions, so parking-heavy assets face real air-quality and congestion pressure. That can push the Company toward EV chargers, lighting upgrades, and traffic-flow controls to meet stricter environmental expectations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClimate risk in New Jersey and Israel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRafael Holdings, Inc. has assets in New Jersey and Israel, two regions facing sharp climate stress. New Jersey coastal flooding has worsened as sea level at Atlantic City has risen about 1.6 feet since 1911, while Israel has seen hotter, drier conditions and more heat strain on buildings and systems.\u003c\/p\u003e\n\u003cp\u003eThat raises operating and maintenance costs, and it can disrupt access, cooling, and utilities. Resilience planning matters for continuity and insurance, especially as insurers price in flood, fire, and extreme-heat risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew Jersey: flood and storm exposure\u003c\/li\u003e\n\u003cli\u003eIsrael: heat and water stress\u003c\/li\u003e\n\u003cli\u003eHigher maintenance and outage risk\u003c\/li\u003e\n\u003cli\u003eInsurance and continuity planning matter\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInvestor ESG expectations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInvestor ESG expectations are rising as public companies face tighter scrutiny on environmental performance, and buildings are a big focus because they drive about 34% of global energy demand and 37% of energy-related CO2 emissions. For Rafael Holdings, Inc., real estate energy use, utility costs, and asset-level footprint can affect investor sentiment, loan terms, and valuation. ESG gaps can also hurt reputation, while better disclosure and lower-emission operations can support access to capital.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuildings drive 37% of energy-related CO2\u003c\/li\u003e\n\u003cli\u003eEnergy use now shapes investor reviews\u003c\/li\u003e\n\u003cli\u003eESG can move financing terms and trust\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRafael Holdings Faces Rising Climate Costs From Buildings, Floods, and Heat\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRafael Holdings, Inc. faces climate risk from energy use, flood exposure, and indoor air demands: buildings still drive about 37% of energy-related CO2, and the EPA says indoor air can be 2 to 5 times dirtier than outdoor air. New Jersey flooding and Israel heat stress can raise repair, utility, and insurance costs, while EV-ready parking and efficient HVAC can help protect occupancy and margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBuildings\u003c\/td\u003e\n\u003ctd\u003e37% of energy-related CO2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndoor air\u003c\/td\u003e\n\u003ctd\u003e2 to 5x more polluted\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTransport\u003c\/td\u003e\n\u003ctd\u003e28% of US GHG emissions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234818793737,"sku":"rfl-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/rfl-pestle-analysis.webp?v=1785730073","url":"https:\/\/dcfanalyst.com\/products\/rfl-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}